Amplia Therapeutics announced its March 2022 quarter updates

Amplia Therapeutics Limited (ASX: ATX) has released its quarterly activities and appendix 4C cash flow reports for the quarter ending 31 March 2022.

• ATX has received Human Research Ethics Committees (HREC) approval to conduct a Phase 2 clinical trial in first-line patients with pancreatic cancer.
• US FDA granted pre-IND meeting request to discuss development plans for AMP945.
• Commenced extended toxicology studies of AMP945 to support Phase 2 clinical trial in lung fibrosis patients and later-stage development.
• Amplia finished the March 2022 quarter with cash of AU$14.609 million (Earlier in December 2021: AU$16.165 million).

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Maven Capital Pty Ltd (AFSL No. 418504). The information contained in this article is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Suite 1A, Level 2, 802-808 Pacific Highway, Gordon NSW 2072, Australia | 1800 005 780 | info@kapitales.com.au